Trial reportBritish journal of clinical pharmacology2017
Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Trial report in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model.Journal of clinical pharmacology · 2019Trial
- Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?British journal of clinical pharmacology · 2017Trial
- Predictors and nomogram of midazolam-induced somnolence: a retrospective cohort study.BMC anesthesiology · 2026Article
- A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker.European journal of clinical pharmacology · 2025Article
- Association between anesthetics and the postoperative pneumonia risk in patients with non-traumatic subarachnoid hemorrhage: an analysis of the MIMIC-IV database.Frontiers in neurology · 2025Article
- Association of NR1I2 Polymorphism with Midazolam Clearance in Mechanically Ventilated ICU Patients: A Population Pharmacokinetic and Pharmacogenetic Study.Drug design, development and therapy · 2025Article
- Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Dose optimization of cefotaxime as pre-emptive treatment in critically ill adult patients: A population pharmacokinetic study.British journal of clinical pharmacology · 2023Article
- Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19.Clinical pharmacokinetics · 2022Article
- Clearance of Lormetazepam, Midazolam, and Their Conjugated Metabolites by Continuous Venovenous Hemofiltration During Prolonged Sedation in Critically Ill Patients With COVID-19-Associated Acute Respiratory Distress Syndrome.Journal of clinical pharmacology · 2022Article
- Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?Pharmaceutics · 2022Article
- Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients.British journal of clinical pharmacology · 2021Article
- LPS-Induced Inflammation Affects Midazolam Clearance in Juvenile Mice in an Age-Dependent Manner.Journal of inflammation research · 2021Article
- Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.Pharmacology & therapeutics · 2020Review
- Midazolam: an essential palliative care drug.Palliative care and social practice · 2020Review
- A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.British journal of clinical pharmacology · 2019Article
- Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life.European journal of drug metabolism and pharmacokinetics · 2019Article
- Palliative Sedation for the Terminally Ill Patient.CNS drugs · 2018Review
- Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients.British journal of clinical pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMidazolam is the drug of choice for palliative sedation and is titrated to achieve the desired level of sedation. Because of large inter-individual variability (IIV), however, the time it takes to achieve adequate sedation varies widely. It would therefore greatly improve clinical care if an individualized dose could be determined beforehand. To find clinically relevant parameters for dose individualization, we performed a pharmacokinetic study on midazolam, 1OH-midazolam (1-OH-M) and 1OH-midazolam-glucuronide (1-OH-MG) in terminally ill patients.
methodsUsing nonlinear mixed effects modelling (NONMEM 7.2), a population pharmacokinetic analysis was conducted with 192 samples from 45 terminally ill patients who received midazolam either orally or subcutaneously. The covariates analysed were patient characteristics, co-medication and blood chemistry levels.
resultsThe data were accurately described by a one compartment model for midazolam, 1-OH-M and 1-OH-MG. The population mean estimates for midazolam, 1-OH-M and 1-OH-MG clearance were 8.4 l h
conclusionOur study indicates albumin levels and eGFR as relevant clinical parameters to optimize midazolam dosing in terminally ill patients. The correlation between low albumin levels and decreased midazolam clearance is probably a result of inflammatory response as high CRP levels were correlated in a similar way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.